Literature DB >> 2105954

Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

K K Hamilton1, R Hattori, C T Esmon, P J Sims.   

Abstract

Assembly of the terminal complement proteins C5b-9 on human endothelial cells results in increased cytosolic calcium and nonlytic secretion of high molecular weight multimers of von Willebrand factor from intracellular storage granules. We now demonstrate that this C5b-9-induced secretory response is accompanied by vesiculation of membrane particles from the endothelial surface which express binding sites for factor Va and support prothrombinase activity. Exposure of factor Va binding sites after C5b-9 assembly was accompanied by greater than 2-fold increase in prothrombinase activity, which was not observed for cells exposed to C5b-8 (in the absence of C9). By contrast, only a 3-16% increase in prothrombinase activity was observed when these cells were maximally stimulated to secrete by either histamine, thrombin, or the Ca2+ ionophore A23187. Increased prothrombinase activity after C5b-9 was not accompanied by a change in thrombomodulin activity, and was unrelated to cell lysis, the complement-treated cells remaining greater than 99% viable. Endothelial prothrombinase activity was predominately associated with small membrane vesicles (less than 1 microns diameter) released from the cell monolayer. Analysis by fluorescence-gated flow cytometry revealed that these vesicles incorporate the C5b-9 proteins and express binding sites for factor Va. The capacity of the C5b-9 proteins to induce vesiculation of the endothelial plasma membrane and thereby expose catalytic surface for the prothrombinase enzyme complex may contribute to fibrin deposition associated with immune endothelial injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105954

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

Review 1.  The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases.

Authors:  Paolo Puddu; Giovanni M Puddu; Eleonora Cravero; Silvia Muscari; Antonio Muscari
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

Review 2.  Ectosomes as immunomodulators.

Authors:  Salima Sadallah; Ceylan Eken; Jürg A Schifferli
Journal:  Semin Immunopathol       Date:  2010-12-07       Impact factor: 9.623

3.  Microparticles in stored red blood cells as potential mediators of transfusion complications.

Authors:  Wenche Jy; Marco Ricci; Sherry Shariatmadar; Orlando Gomez-Marin; Lawrence H Horstman; Yeon S Ahn
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

4.  Microparticles during sepsis: target, canary or cure?

Authors:  Lara Zafrani; Can Ince; Peter S T Yuen
Journal:  Intensive Care Med       Date:  2013-08-08       Impact factor: 17.440

Review 5.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

Review 6.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

7.  Phosphatidylserine-mediated adhesion of T-cells to endothelial cells.

Authors:  J Qu; L A Conroy; J H Walker; F B Wooding; J A Lucy
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

8.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

9.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

10.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.